Experience

Davis Polk advised Notre Dame Intermédica Participações S.A. in connection with the equity offering by Notre Dame Intermédica and Bain Capital, a shareholder of Notre Dame Intermédica, of…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $195.6 million public offering of common stock of Forty Seven, …

Davis Polk advised Roche on its approximately $4.3 billion acquisition of Spark Therapeutics, Inc., including coordinating all international regulatory filings.  The acquisition was…

Davis Polk advised the initial purchasers in connection with the $110.5 million Regulation S only offering by Tahoe Group Global (Co.,) Limited of its 11.0% senior notes due 2020. The notes…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the $224.3 million offering of common stock of Constellation…

Davis Polk advised LIV Capital Acquisition Corp. on its $70 million initial public offering of 7,000,000 units. Each unit had an initial offering price of $10 and consists of one Class A…

Davis Polk advised Ranpak Holdings Corp. in connection with the $110 million SEC-registered offering of 16,923,077 shares of its Class A common stock, including 1,538,461 shares pursuant to…

Davis Polk advised XP Inc. on its $2.25 billion initial public offering of 83,387,237 Class A common shares, consisting of 42,553,192 shares sold by XP and 40,834,045 shares sold by…

Davis Polk advised an ad hoc group of senior unsecured noteholders in connection with the chapter 11 cases of Legacy Reserves, Inc. and certain of its subsidiaries (collectively, “Legacy”)…

Davis Polk is advising Universal Scientific Industrial (Shanghai) Co., Ltd. on its acquisition of Asteelflash. Under the terms of the transaction agreement, USI will acquire 100% of the…